Phase 3 trials – Talk Bio

Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

8 months ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

Incyte’s oral HS drug hits study goals, but fails to excite investors

10 months ago talkbio0Tagged Effectiveness, Hidradenitis, Inhibitor, investor, Janus kinase 1, Phase 3 trials, povorcitinib, regulatory, suppurativa

povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission

Merck’s HIV Combo Treatment Advances Towards FDA Filing

11 months ago talkbio0Tagged DOR/ISL, doravirine/islatravir, once-daily, oral regimen, Phase 3 trials, Submission, United States Food and Drug Administration, viral suppression

Doravirine/islatravir (DOR/ISL) combination, Phase 3 trials, Viral suppression, Once-daily oral regimen, FDA submission

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

12 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Royalty Pharma Invests $250M in Biogen’s Late-Stage Lupus Treatment

12 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, Phase 3 trials, R&D funding, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

12 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation